Daphne Y. Lichtensztajn

Daphne Y. Lichtensztajn

Auto-generated profile, based on publicly available information

Daphne Y. Lichtensztajn

Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MGMariana Chavez Chavez Mac Gregor
Mariana Chavez Chavez Mac Gregor
CCChristina A. Clarke
Christina A. Clarke
DLDaphne Y. Lichtensztajn
Daphne Y. Lichtensztajn
SGSharon H. Giordano
Sharon H. Giordano
In 2015, an estimated 231 840 cases of invasive breast cancer were diagnosed in the United States.1 Improvements in breast cancer treatment and early detection have resulted in a decrease in the mortality rates of patients with breast cancer in the last decades. Among patients with early-stage breast cancer, the use of adjuvant chemotherapy has had a dramatic effect decreasing the risk of recurrence and improving survival rates.2

29 March 2012 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
TGthe AYA HOPE Study Collaborative Group
the AYA HOPE Study Collaborative Group
TKTheresa H. M. Keegan
Theresa H. M. Keegan
DLDaphne Y. Lichtensztajn
Daphne Y. Lichtensztajn
IKIkuko Kato
Ikuko Kato
EKErin E. Kent
Erin E. Kent
ASAshley W. Smith
Ashley W. Smith

1 February 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
AWAnna Weiss
Anna Weiss
MGMariana Chavez Chavez Mac Gregor
Mariana Chavez Chavez Mac Gregor
DLDaphne Y. Lichtensztajn
Daphne Y. Lichtensztajn
MYMin Yi
Min Yi
ATAudree Tadros
Audree Tadros
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
The goals of cancer staging are to determine the extent of disease, help implement a treatment plan, and inform prognosis. Historically, the American Joint Committee on Cancer (AJCC) staging system for breast cancer has assigned stage based on tumor size (T), the presence of lymph node involvement (N), and the presence or absence of distant metastasis (M). The T, N, and M categories are determined, and this corresponds with a specific disease stage.

19 October 2010 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MTMelinda L. Telli
Melinda L. Telli
ECEllen T. Chang
Ellen T. Chang
AKAllison W. Kurian
Allison W. Kurian
TKTheresa H. M. Keegan
Theresa H. M. Keegan
LMLaura A. McClure
Laura A. McClure
SGScarlett L. Gomez
Scarlett L. Gomez

22 January 2013 in Cancer
Verified
Journal Article
Open access
PDF file
MGMariana Chavez Chavez Mac Gregor
Mariana Chavez Chavez Mac Gregor
CCChristina A. Clarke
Christina A. Clarke
DLDaphne Lichtensztajn
Daphne Lichtensztajn
GHGabriel N. Hortobagyi
Gabriel N. Hortobagyi
SGSharon H. Giordano
Sharon H. Giordano
BACKGROUND: Breast cancer occurs rarely in men. To the authors' knowledge, no population‐based estimates of the incidence of human epidermal growth factor receptor 2 (HER2)‐positive breast cancer or of the distribution of breast cancer subtypes among male breast cancer patients have been published to date. Therefore, the objective of the current study was to explore breast tumor subtype distribution by race/ethnicity among men in the large, ethnically diverse population of California.METHODS: This study included men who were diagnosed with invasive breast cancer between 2005 and 2009 with known estrogen receptor (ER) and progesterone receptor (PR) (together, hormone receptor [HR]) status and HER2 status reported to the California Cancer Registry. Among the men with HR‐positive tumors, survival probabilities between groups were compared using log‐rank tests.RESULTS: Six hundred six patients were included. The median age at diagnosis was 68 years. Four hundred ninety‐four men (81.5%) had HR‐positive tumors (defined as ER‐positive and/or PR‐positive and HER2‐negative). Ninety men (14.9%) had HER2‐positive tumors, and 22 (3.6%) had triple receptor‐negative (TN) tumors. Among the patients with HR‐positive tumors, non‐Hispanic black men and Hispanic men were more likely to have PR‐negative tumors than non‐Hispanic white men. No statistically significant differences in survival were observed according to tumor subtype (P = .08). Differences in survival according to race/ethnicity were observed among all patients (P = .087) and among those with HR‐positive tumors (P = .0170), and non‐Hispanic black men had poorer outcomes.CONCLUSIONS: In this large, representative cohort of men with breast cancer, the distribution of tumor subtypes was different from that reported for women and varied by patient race/ethnicity. Non‐Hispanic black men were more likely to have TN tumors and ER‐positive/PR‐negative tumors than white men. Cancer 2013. © 2013 American Cancer Society.

3 May 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
John Thomas HelgstrandJohn Thomas Helgstrand
John Thomas Helgstrand
Martin Andreas RøderMartin Andreas Røder
Martin Andreas Røder
NKNina Klemann
Nina Klemann
BTBirgitte G. Toft
Birgitte G. Toft
DLDaphne Y. Lichtensztajn
Daphne Y. Lichtensztajn
PIPeter Iversen
Peter Iversen